ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 95 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $763,383 | +3.0% | 48,438 | -1.0% | 0.00% | 0.0% |
| Q4 2023 | $741,092 | -26.6% | 48,917 | -2.8% | 0.00% | 0.0% |
| Q3 2023 | $1,009,178 | -40.2% | 50,308 | -15.9% | 0.00% | -50.0% |
| Q2 2023 | $1,687,325 | +162.5% | 59,813 | +60.1% | 0.00% | +100.0% |
| Q1 2023 | $642,747 | -14.6% | 37,369 | +0.0% | 0.00% | 0.0% |
| Q4 2022 | $752,369 | -8.0% | 37,357 | -1.0% | 0.00% | 0.0% |
| Q3 2022 | $818,000 | -17.8% | 37,732 | +6.6% | 0.00% | 0.0% |
| Q2 2022 | $995,000 | +9.9% | 35,393 | +80.3% | 0.00% | 0.0% |
| Q1 2022 | $905,000 | -38.0% | 19,629 | +13.1% | 0.00% | 0.0% |
| Q4 2021 | $1,459,000 | +76.4% | 17,351 | +39.9% | 0.00% | – |
| Q3 2021 | $827,000 | +26.8% | 12,398 | +1.3% | 0.00% | – |
| Q2 2021 | $652,000 | +15.8% | 12,235 | -5.6% | 0.00% | – |
| Q1 2021 | $563,000 | -65.4% | 12,965 | -58.7% | 0.00% | -100.0% |
| Q4 2020 | $1,629,000 | – | 31,374 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 187,143 | $765,415 | 25.27% |
| Decheng Capital LLC | 3,070,442 | $12,558,107 | 3.85% |
| MPM BioImpact LLC | 1,450,000 | $5,930,500 | 0.92% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $3,932,478 | 0.80% |
| Eventide Asset Management | 8,547,896 | $34,960,895 | 0.60% |
| 5AM Venture Management, LLC | 490,000 | $2,004,100 | 0.45% |
| Matrix Capital Management Company, LP | 13,959,973 | $57,096,290 | 0.44% |
| Values First Advisors, Inc. | 74,925 | $306,443 | 0.18% |
| Boxer Capital, LLC | 450,000 | $1,840,500 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 255,201 | $1,044 | 0.07% |